People with cancer of the nasopharynx, an area behind the nose, may benefit from a new combination therapy, according to an international study led by Memorial Sloan-Kettering radiation oncologist Nancy Y. Lee.

Five Memorial Sloan-Kettering scientists have been appointed to a new research team dedicated to identifying targets for therapies to treat a certain form of melanoma.

Congratulations to Mark Kris, Chief of the Thoracic Oncology Service, and Ann Culkin, nurse on the Thoracic Oncology Service, for receiving the Wholeness of Life Award 2011 from the HealthCare Chaplaincy.

Recent findings by Memorial Sloan-Kettering investigators suggest it might be possible to improve the effectiveness of chemotherapy for breast cancer by combining the treatment with a new type of drug called a cathepsin inhibitor.

Research led by investigators at Memorial Sloan-Kettering has identified a previously unknown mechanism of resistance to the newly approved melanoma drug vemurafenib.

Research published in the November 19 issue of The Lancet finds that MRI use for breast cancer screening in women at high risk for the disease – due to family history or a genetic mutation – detects more cancers than screening mammography.